Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the effect of administration of the oral
beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with
cervical (neck) and high thoracic (upper back) spinal cord injury and to compare findings
with those obtained in a demographically matched group that will receive placebo.
Participation in this study will involve 12 weeks of pharmacological intervention during
which participants will be randomized to receive either oral albuterol 4mg twice daily or
placebo. All investigators and study participants will be blinded to randomization by our
research pharmacy. Participation in the study will require study subjects to come to our lab
for the total of 2 visits (at baseline and after week 12), during which a series of tests
will be performed to assess their respiratory muscle strength and pulmonary function.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development